EPCAM and prostate cancer: To investigate the role of the tumour microenvironment in patient outcome, we enriched for four cell populations (epithelial: EpCAM+; fibroblasts CD90+/CD31−; T cells: CD45+/CD3+; and myeloid: CD45+/CD16+) from fresh prostatectomies of 13 prostate cancers, ranging from benign tissue (labelled as CAPRA-S score 0) to high-risk tumours (CAPRA-S risk score 7).